Eli Lilly & Co. trained its sales force to downplay risks for Zyprexa and encourage doctors to prescribe the drug beyond approved uses for schizophrenia and bipolar disorder, according to court documents.
Lilly's research showed some patients on Zyprexa gained as much as 80 pounds and that the incidence of high blood sugar at diabetes levels was 3.5 times higher than for placebos, according to documents filed in a lawsuit brought by the state of Alaska.
The U.S. is seeing a late summer surge in COVID-19 cases, tracking from the Centers for...
The US’s top public health agency was plunged into chaos on Wednesday after the Trump administration...
Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last...
